- Evonik is collaborating with KNAUER Wissenschaftliche Geräte GmbH to improve lipid nanoparticle (LNP) scale-up and efficiency.
- The partnership aims to shorten preclinical development times and enhance the transition from prototype to GMP production.
Evonik is partnering with KNAUER Wissenschaftliche Geräte GmbH to enhance the scale-up process for lipid nanoparticle (LNP) formulations. The collaboration aims to improve efficiency and speed up the transition from small-scale prototypes to production-scale formulations, reducing preclinical development time.
The joint effort combines Evonik’s expertise in formulation and scale-up with KNAUER’s technological capabilities. Recent implementation of KNAUER’s IJM NanoScaler Pro technology addresses challenges in nucleic acid LNP formulations by cutting down on time-consuming experiments and reducing material costs.
Andrea Engel, Head of Growth Projects at Evonik Health Care, commented, “Together with KNAUER, we can increase the speed with which we go from very small-scale prototypes to production-scale lead formulations, and then directly into GMP production of drug products.”
Evonik supplies lipids and LNP drug development services globally, with the LNP market estimated at over $600 million and expected to grow. The company’s Vancouver Laboratories and cGMP facility in Hanau, Germany, are key components of its network, with a new manufacturing facility under construction at the Tippecanoe, IN site for rapid scale-up of specialty lipids.
Anja Fuss, Head of Purification & Customized Solutions at KNAUER, added, “By working hand-in-hand with Evonik, we are confident that our areas of expertise complement each other, and that exceptional formulation and technology will lead to improved patient outcomes.”
Overview of outsourcing trends 
